Chiasma Inc. (CHMA) and Agenus Inc. (NASDAQ:AGEN) Contrasting side by side

Chiasma Inc. (NASDAQ:CHMA) and Agenus Inc. (NASDAQ:AGEN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chiasma Inc. N/A 0.00 29.29M -1.16 0.00
Agenus Inc. 38.69M 11.42 147.18M -1.40 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Chiasma Inc. and Agenus Inc.


Table 2 shows us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Chiasma Inc. 0.00% -56.3% -48.6%
Agenus Inc. -380.41% 136.2% -110.7%

Volatility & Risk

A beta of 1.11 shows that Chiasma Inc. is 11.00% more volatile than S&P 500. Agenus Inc.’s 127.00% more volatile than S&P 500 which is a result of the 2.27 beta.


Chiasma Inc. has a Current Ratio of 5.6 and a Quick Ratio of 5.6. Competitively, Agenus Inc.’s Current Ratio is 1.2 and has 1.2 Quick Ratio. Chiasma Inc.’s better ability to pay short and long-term obligations than Agenus Inc.

Institutional & Insider Ownership

The shares of both Chiasma Inc. and Agenus Inc. are owned by institutional investors at 66.7% and 32.4% respectively. Insiders owned 0.3% of Chiasma Inc. shares. On the other hand, insiders owned about 0.1% of Agenus Inc.’s shares.


In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Chiasma Inc. -10.2% -11.52% 38.85% 148.97% 95.14% 112.35%
Agenus Inc. 9.13% 27.05% 32.83% -9.62% -27.35% -19.33%

For the past year Chiasma Inc. has 112.35% stronger performance while Agenus Inc. has -19.33% weaker performance.


Chiasma Inc. beats Agenus Inc. on 6 of the 9 factors.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.